Poor post-induction outcomes in patients with acute myeloid leukemia previously treated with hypomethylating agents

被引：1

作者：

Zhang, Michelle Y. Y. ^{[1
]}

Othus, Megan ^{[2
]}

Shaw, Carole ^{[3
]}

Schonhoff, Kelda G. G. ^{[1
]}

Halpern, Anna B. B. ^{[1
,3
]}

Appelbaum, Jacob ^{[1
]}

Hendrie, Paul C. C. ^{[1
]}

Walter, Roland B. B. ^{[1
,3
,4
,5
]}

Estey, Elihu H. H. ^{[1
,3
]}

Percival, Mary-Elizabeth M. ^{[1
,3
,6
]}

机构：

[1] Univ Washington, Dept Med, Seattle, WA USA

[2] Fred Hutchinson Canc Res Ctr, Publ Hlth Sci Div, Seattle, WA USA

[3] Fred Hutchinson Canc Res Ctr, Clin Res Div, Seattle, WA USA

[4] Univ Washington, Dept Lab Med & Pathol, Seattle, WA USA

[5] Univ Washington, Dept Epidemiol, Seattle, WA USA

[6] 825 Eastlake Ave E,MS LG-700, Seattle, WA 98109 USA

来源：

LEUKEMIA & LYMPHOMA | 2023年 / 64卷 / 05期

关键词：

Hypomethylating agent; acute myeloid leukemia; outcomes; high intensity induction; MYELODYSPLASTIC SYNDROME; AZACITIDINE; THERAPY; INDUCTION; RISK; VENETOCLAX; CYTARABINE; EFFICACY; ADULTS;

D O I：

10.1080/10428194.2023.2186732

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Patients with acute myeloid leukemia (AML) who have failed hypomethylating agents (HMA) have a poor prognosis. We examined whether high intensity induction chemotherapy could abrogate negative outcomes in 270 patients with AML or other high-grade myeloid neoplasms. Prior HMA therapy was significantly associated with a lower overall survival (OS) as compared to a reference group of patients with secondary disease without prior HMA therapy (median 7.2 vs 13.1 months). In patients with prior HMA therapy, high intensity induction was associated with a non-significant trend toward longer OS (median 8.2 vs 4.8 months) and decreased rates of treatment failure (39% vs 64%). These results redemonstrate poor outcomes in patients with prior HMA and suggest possible benefit of high intensity induction that should be evaluated in future studies.

引用

页码：990 / 996

页数：7

共 32 条

[21] Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers [J].

Li, Huili ;

Chiappinelli, Katherine B. ;

Guzzetta, Angela A. ;

Easwaran, Hariharan ;

Yen, Ray-Whay Chiu ;

Vatapalli, Rajita ;

Topper, Michael J. ;

Luo, Jianjun ;

Connolly, Roisin M. ;

Azad, Nilofer S. ;

Stearns, Vered ;

Pardoll, Drew M. ;

Davidson, Nancy ;

Jones, Peter A. ;

Slamon, Dennis J. ;

Baylin, Stephen B. ;

Zahnow, Cynthia A. ;

Ahuja, Nita .

ONCOTARGET, 2014, 5 (03) :587-598

[22] Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study [J].

Ostgard, Lene Sofie Granfeldt ;

Medeiros, Bruno C. ;

Sengelov, Henrik ;

Norgaard, Mette ;

Andersen, Mette Klarskov ;

Dufva, Inge Hogh ;

Friis, Lone Smidstrup ;

Kjeldsen, Eigil ;

Marcher, Claus Werenberg ;

Preiss, Birgitte ;

Severinsen, Marianne ;

Norgaard, Jan Maxwell .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (31) :3641-+

[23] Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure [J].

Prebet, Thomas ;

Gore, Steven D. ;

Esterni, Benjamin ;

Gardin, Claude ;

Itzykson, Raphael ;

Thepot, Sylvain ;

Dreyfus, Francois ;

Rauzy, Odile Beyne ;

Recher, Christian ;

Ades, Lionel ;

Quesnel, Bruno ;

Beach, C. L. ;

Fenaux, Pierre ;

Vey, Norbert .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (24) :3322-3327

[24] Hypomethylating agents in the treatment of acute myeloid leukemia: A guide to optimal use [J].

Santini, Valeria ;

Ossenkoppele, Gert J. .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, 140 :1-7

[25] Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party [J].

Schuurhuis, Gerrit J. ;

Heuser, Michael ;

Freeman, Sylvie ;

Bene, Marie-Christine ;

Buccisano, Francesco ;

Cloos, Jacqueline ;

Grimwade, David ;

Haferlach, Torsten ;

Hills, Robert K. ;

Hourigan, Christopher S. ;

Jorgensen, Jeffrey L. ;

Kern, Wolfgang ;

Lacombe, Francis ;

Maurillo, Luca ;

Preudhomme, Claude ;

van der Reijden, Bert A. ;

Thiede, Christian ;

Venditti, Adriano ;

Vyas, Paresh ;

Wood, Brent L. ;

Walter, Roland B. ;

Doehner, Konstanze ;

Roboz, Gail J. ;

Ossenkoppele, Gert J. .

BLOOD, 2018, 131 (12) :1275-1291

[26] Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study [J].

Slovak, ML ;

Kopecky, KJ ;

Cassileth, PA ;

Harrington, DH ;

Theil, KS ;

Mohamed, A ;

Paietta, E ;

Willman, CL ;

Head, DR ;

Rowe, JM ;

Forman, SJ ;

Appelbaum, FR .

BLOOD, 2000, 96 (13) :4075-4083

[27] Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis [J].

Stein, Eytan M. ;

Bonifacio, Gaetano ;

Latremouille-Viau, Dominick ;

Shi, Sherry ;

Guerin, Annie ;

Wu, Eric Q. ;

Sadek, Islam ;

Cao, Xiting .

JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) :234-243

[28] Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome [J].

Stetler-Stevenson, M ;

Arthur, DC ;

Jabbour, N ;

Xie, XY ;

Molldrem, J ;

Barrett, AJ ;

Venzon, D ;

Rick, ME .

BLOOD, 2001, 98 (04) :979-987

[29] Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies [J].

Stomper, Julia ;

Rotondo, John Charles ;

Greve, Gabriele ;

Luebbert, Michael .

LEUKEMIA, 2021, 35 (07) :1873-1889

[30] Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy [J].

Talati, Chetasi ;

Goldberg, Aaron D. ;

Przespolewski, Amanda ;

Chan, Onyee ;

Al Ali, Najla ;

Kim, Jongphil ;

Famulare, Chris ;

Sallman, David ;

Padron, Eric ;

Kuykendall, Andrew ;

Lancet, Jeffrey E. ;

Wang, Eunice ;

Tallman, Martin S. ;

Komrokji, Rami ;

Sweet, Kendra .

LEUKEMIA RESEARCH, 2020, 93

← 1 2 3 4 →